GENinCode PLC (GENI)
Industry Diagnostics & Research
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
2.70p
Buy
2.90p
0.00p (+0.00%)
Prices updated at 12 Dec 2025, 13:57 GMT
| Prices minimum 15 mins delay
Prices in GBX
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Diagnostics & Research
Chairman
Mr. William E. Rhodes III
CEO
Mr. Matthew Heaton Walls
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
36
Head office
Oxford Science Park
Oxford
United Kingdom
OX4 4GP
Key personnel
Owner name | Salary |
|---|---|
Mr. William E. Rhodes III Non-Executive Director, Chairman | - |
Mr. Sergio Olivero Rigau Non-Executive Director | - |
Professor Huon Gray CBE Non-Executive Director | - |
Mr. Felix Wilhelm Frueh Non-Executive Director | - |
Mr. Jordi Puig Gilberte Executive Director, Founder and Chief Operations Officer | - |
Mr. Paul Andrew Peter Foulger Executive Director, Chief Financial Officer and Company Secretary | - |
Mr. Matthew Heaton Walls Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Chelverton Asset Management Ltd | 13,639,371 |
| MI Chelverton UK Equity Growth Fund | 13,639,371 |
| Diverinvest Asesoramiento EAFI | 5,945,945 |
| Jungleland Value SIL | 5,945,945 |
| Maven Capital Partners UK LLP | - |
Director dealings
Date | Action |
|---|---|
| 04 Mar 2025 | Purchase |
| 04 Mar 2025 | Purchase |
| 04 Mar 2025 | Purchase |
| 04 Mar 2025 | Purchase |
| 04 Mar 2025 | Purchase |
Please note that past performance is not a reliable indicator of future returns.
